Overview
Tirzepatide is a dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and weight management.
Preparation
Reconstitute a 10mg vial with 2mL BAC for a concentration of 5mg/mL.
Protocol
| Period | Dose | Units (@ 5mg/mL) | Frequency |
|---|---|---|---|
| Weeks 1-4 | 2.5 mg | 50 u | 1x/week |
| Weeks 5-8 | 5 mg | 100 u | 1x/week |
| Weeks 9-12 | 7.5 mg | 150 u | 1x/week |
| Weeks 13-16 | 10 mg | 200 u | 1x/week |
| Weeks 17-20 | 12.5 mg | 250 u | 1x/week |
| Weeks 21-24 | 15 mg | 300 u | 1x/week |
Cycle
12 weeks on, 4 weeks off.